AstraZeneca, Bristol-Myers Squibb in Merger Talks, Report Says

AstraZeneca PLC and Bristol-Myers Squibb Co. have held discussions in recent months about a potential merger, a move that would form one of the world's largest pharmaceutical companies, according to a Financial Times report citing people familiar with the matter.

The Potential Deal

A combination of the two drugmakers would create an entity with a market value of nearly $400 billion. Based on current valuations, AstraZeneca has a market capitalization of approximately $264 billion, while Bristol-Myers Squibb is valued at roughly $133 billion.

The discussions were described as preliminary, and the report cautioned that they could be delayed or fall apart entirely. The sources did not disclose a potential deal structure. Both AstraZeneca and Bristol-Myers Squibb have not provided official comments on the matter.

Strategic Rationale and Hurdles

For Bristol-Myers Squibb, a merger could accelerate the diversification of its drug pipeline, which faces pressure from looming patent expirations. The company has actively pursued acquisitions to bolster its oncology and immunology assets. For AstraZeneca, the strategic fit would need to be reconciled with its recent plans for a direct U.S. listing and a $50 billion investment commitment in U.S. manufacturing and research.

Ad

A cross-border merger of this magnitude would face formidable regulatory challenges. The deal would almost certainly trigger in-depth antitrust reviews from multiple agencies, including the U.S. Federal Trade Commission (FTC), the UK's Competition and Markets Authority (CMA), and the European Commission.

Market Context

Both companies reported strong second-quarter earnings. Bristol-Myers Squibb has seen its stock gain approximately 47.7% over the past year, closing Friday near its 52-week high. AstraZeneca's share price has more than quadrupled since it successfully rebuffed a $118 billion takeover bid from Pfizer in 2014 under CEO Pascal Soriot.

Investors will be watching market open on Monday for the first reaction to the report. The next scheduled corporate updates are in late October, with Bristol-Myers Squibb reporting Q3 results on October 29 and AstraZeneca on October 30.